Feb 02, 2022 7:00am EST Unicycive Announces Renazorb Pre-clinical and Clinical Data Selected for Presentation at National Kidney Foundation Spring Clinical Meeting
Jan 10, 2022 7:00am EST Unicycive Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
Nov 29, 2021 7:00am EST Unicycive Therapeutics Receives Confirmatory Guidance on Renazorb Regulatory Pathway
Oct 26, 2021 7:30am EDT Unicycive Therapeutics Appoints Douglas Jermasek As Executive Vice President, Corporate Strategy
Sep 07, 2021 6:00am EDT Unicycive Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Dec 14, 2020 9:30am EST Unicycive Therapeutics Acquires Renazorb (Lanthanum Dioxycarbonate) from Spectrum Pharmaceuticals for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease
